These pharmacological studies in patient-derived xenograft models however also indicate that HIF-2α specific inhibition is not sufficient to inhibit the growth of all ccRCCs25, suggesting that other oncogenic drivers may be important in some or all tumours. Here, EPAS1 is linked to neoplasm.